Ground News

Understand Every Side.

modernretina.com image

News from modernretina.com

See all of modernretina.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

In total, 149 have been published by modernretina.com which Ground News has aggregated in the past 3 months.

The Ground News media bias check for modernretina.com is unknown. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

modernretina.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about modernretina.com

Where is modernretina.com located?modernretina.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top modernretina.com News

Roche’s Susvimo Approved by FDA for Diabetic Retinopathy

United States · United States

Roche’s Susvimo Approved by FDA for Diabetic Retinopathy

100% Right coverage: 1 sources

Breakthrough eye implant treats diabetic retinopathy with just 2 treatments yearly vs monthly injections. See how this FDA-approved device transforms patient care.See the Story

Study highlights retinal vulnerability in patients with bipolar and depressive disorders

Alzheimer's Disease

Study highlights retinal vulnerability in patients with bipolar and depressive disorders

Retinal vascular change or degeneration already has been associated with Alzheimer and Parkinson disease, and the findings suggest that neurologic diseases impact ocular health.See the Story

Ocular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMD

Ocular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMD

The trial will evaluate AXPAXLI in at least 555 patients in a multi-center, double-masked, randomized (2:2:1), 3-arm study.See the Story

Retina World Congress: Global innovations transforming treatment strategies

International retina specialists converge to explore groundbreaking treatments, drug delivery systems, and surgical innovations at the Retina World Congress 2025.Read Article

Bilateral central retinal artery occlusion following paclitaxel therapy

The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.See the Story

Rapid Improvements In DME With Next-Generation Anti-VEGF Therapies: Case Highlights

Dilsher S. Dhoot, MD discusses how second-generation anti-VEGF agents like aflibercept 8mg and faricimab demonstrate significant efficacy in treating diabetic macular edema (DME), allowing for extended treatment intervals of 9-10 weeks compared to monthly dosing with earlier agents, while improving anatomic outcomes and visual acuity.Read Article

Innovative suprachoroidal injection reduces diabetic retinopathy complications

Breakthrough suprachoroidal injection technique offers promising treatment for diabetic retinopathy, reducing visual threatening complications from 37% to 4% with minimal inflammation and office-based procedure.Read Article

Improved Retinal Drying and Treatment Durability In nAMD Qith Aflibercept 8mg

Dilsher S. Dhoot, MD discusses how newer anti-VEGF treatments, particularly aflibercept 8mg, can provide improved anatomic outcomes and extended treatment intervals for patients with neovascular AMD who show persistent subretinal fluid despite treatment with first-generation agents.Read Article

Geographic atrophy treatment: High attrition rates challenge long-term patient compliance

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement.Read Article

Faricimab improves vision for minority patients with diabetic macular edema

Study reveals faricimab effectively treats diabetic macular edema in underrepresented minorities, showing significant visual acuity improvements and safety across diverse patient populations.Read Article

Post hoc analysis of GATHER1 and GATHER2 data

New analysis reveals the ellipsoidal zone's role in predicting geographic atrophy progression, enabling timely interventions to protect photoreceptors.Read Article

Breaking News Topics Related to modernretina.com